Published in Cell Mol Biol (Noisy-le-grand) on March 01, 2001
Association between erythrocyte Na+K+-ATPase activity and some blood lipids in type 1 diabetic patients from Lagos, Nigeria. BMC Endocr Disord (2007) 0.80
C-Peptide effects on renal physiology and diabetes. Exp Diabetes Res (2008) 0.80
Protective Effects of Ferulic Acid on High Glucose-Induced Protein Glycation, Lipid Peroxidation, and Membrane Ion Pump Activity in Human Erythrocytes. PLoS One (2015) 0.77
Silent myocardial ischemia in patients with diabetes: who to screen. Diabetes Care (1999) 3.05
Obesity-associated gut microbiota is enriched in Lactobacillus reuteri and depleted in Bifidobacterium animalis and Methanobrevibacter smithii. Int J Obes (Lond) (2011) 2.39
[Prevalence and risk factors of hepatitis C virus infection in a hospitalized population in a gastroenterology unit. Role of endoscopic biopsies]. Gastroenterol Clin Biol (1995) 2.01
Role of transforming growth factor beta type II receptor in hepatic fibrosis: studies of human chronic hepatitis C and experimental fibrosis in rats. Hepatology (1999) 1.90
[Inflammatory rheumatism flare-up after surgical treatment of Cushing's disease: two cases]. Rev Med Interne (1993) 1.51
The defective glucose sensitivity of the B cell in non insulin dependent diabetes. Improvement after twenty hours of normoglycaemia. Metabolism (1982) 1.46
The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. Diabetes Care (1996) 1.41
Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia (1991) 1.41
[Post-acute long stay and extensive rehabilitation: study of the first year of work at a long stay university hospital unit]. Ann Ital Med Int (2001) 1.40
Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients--relationship with plasma insulin. Thromb Haemost (1989) 1.38
[Transparietal spontaneous migration: a complication related to the use of a new material of percutaneous endoscopic gastrostomy?]. Gastroenterol Clin Biol (1994) 1.37
Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism (1986) 1.30
Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab (2005) 1.30
Foveal avascular zone in diabetic retinopathy: quantitative vs qualitative assessment. Eye (Lond) (2005) 1.29
Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels. Circulation (1997) 1.21
Interference of dapsone in HbA1c monitoring of a diabetic patient with polychondritis. Diabetes Metab (2002) 1.17
Decentralising tuberculosis case management in two districts of Burkina Faso. Int J Tuberc Lung Dis (2006) 1.13
Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med (1999) 1.12
The Medi-RIVAGE study (Mediterranean Diet, Cardiovascular Risks and Gene Polymorphisms): rationale, recruitment, design, dietary intervention and baseline characteristics of participants. Public Health Nutr (2004) 1.12
Multivariate analysis of pathophysiological factors in reflux oesophagitis. Gut (1997) 1.08
Abnormalities of erythrocyte deformability and platelet aggregation in insulin-dependent diabetics corrected by insulin in vivo and in vitro. Lancet (1982) 1.08
Insulin-induced lipoatrophy in type I diabetes. A possible tumor necrosis factor-alpha-mediated dedifferentiation of adipocytes. Diabetes Care (1996) 1.05
Observations on the critical micellar concentration of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine and a series of its homologs and analogs. Chem Phys Lipids (1984) 1.00
Hydrolysis of mixed monomolecular films of triglyceride/lecithin by pancreatic lipase. J Biol Chem (1979) 0.99
Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1. Diabete Metab (1987) 0.96
Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma insulin and acute-phase response. Arteriosclerosis (1989) 0.96
Effects of proinsulin C-peptide on nitric oxide, microvascular blood flow and erythrocyte Na+,K+-ATPase activity in diabetes mellitus type I. Clin Sci (Lond) (2000) 0.96
C-peptide replacement improves weight gain and renal function in diabetic rats. Diabetes Metab (2006) 0.95
Molecular cloning of a human gastric lipase and expression of the enzyme in yeast. Biochim Biophys Acta (1987) 0.94
C-peptide, Na+,K(+)-ATPase, and diabetes. Exp Diabesity Res (2004) 0.94
Role of vildagliptin in managing type 2 diabetes mellitus in the elderly. Curr Med Res Opin (2010) 0.93
Kinetic assay of human gastric lipase on short- and long-chain triacylglycerol emulsions. Gastroenterology (1986) 0.93
Preoperative parameters influencing survival in patients with elective portacaval shunts. Digestion (1974) 0.91
Increased PA-inhibitor levels in the postoperative period--no cause-effect relation with increased cortisol. Thromb Haemost (1985) 0.91
A new kinetic approach for studying phospholipase C (Clostridium perfringens alpha toxin) activity on phospholipid monolayers. Biochemistry (1988) 0.91
Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann Med (1996) 0.91
Accumulation of triglyceride-rich lipoprotein in subjects with abdominal obesity: the biguanides and the prevention of the risk of obesity (BIGPRO) 1 study. Arterioscler Thromb Vasc Biol (2001) 0.91
Quantitative analysis of transforming growth factor beta 1 messenger RNA in the liver of patients with chronic hepatitis C: absence of correlation between high levels and severity of disease. Hepatology (1995) 0.91
Alternatives routes of insulin delivery. Diabetes Metab (2006) 0.91
Absence of human papillomavirus DNA detected by polymerase chain reaction in French patients with esophageal carcinoma. Gastroenterology (1995) 0.91
Novel intestinal phospholipase A2: purification and some molecular characteristics. Biochemistry (1982) 0.91
Metabolic behavior of acetyl glyceryl ether phosphorylcholine on interaction with rabbit platelets. Arch Biochem Biophys (1983) 0.91
Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity. Diabetes Care (1998) 0.90
Fish oil supplementation prevents diabetes-induced nerve conduction velocity and neuroanatomical changes in rats. J Nutr (1999) 0.90
Advances in pump technology: insulin patch pumps, combined pumps and glucose sensors, and implanted pumps. Diabetes Metab (2011) 0.90
Circulating albumin messenger RNA in hepatocellular carcinoma: results of a multicenter prospective study. Hepatology (1997) 0.90
Low plasma levels of pancreatic polypeptide in obesity. Diabetes (1980) 0.90
The effects ex vivo and in vitro of insulin and C-peptide on Na/K adenosine triphosphatase activity in red blood cell membranes of type 1 diabetic patients. Metabolism (2000) 0.90
Plasma C-peptide levels and clinical remissions in recent-onset type I diabetic patients treated with cyclosporin A and insulin. Diabetes (1990) 0.89
TT virus infection in French hemodialysis patients: study of prevalence and risk factors. J Clin Microbiol (1999) 0.89
Epidemiology and costs of diabetes treated with insulin in France. Diabetes Metab (2005) 0.89
Changes in plasma lipids and lipoprotein cholesterol during a high altitude mountaineering expedition (4800 m). Eur J Appl Physiol Occup Physiol (1988) 0.89
Two functional Na+/K(+)-ATPase isoforms in the left ventricle of guinea pig heart. Eur J Biochem (1991) 0.88
Erythrocyte Na/K ATPase activity and diabetes: relationship with C-peptide level. Diabetologia (1998) 0.88
Alteration of Na,K-ATPase isoenzymes in diabetic cardiomyopathy: effect of dietary supplementation with fish oil (n-3 fatty acids) in rats. Diabetologia (1997) 0.88
Treatment with metformin of non-diabetic men with hypertension, hypertriglyceridaemia and central fat distribution: the BIGPRO 1.2 trial. Diabetes Metab Res Rev (2000) 0.87
In vivo insulin effect on ATPase activities in erythrocyte membrane from insulin-dependent diabetics. Diabetes (1987) 0.87
[History, accuracy and precision of SMBG devices]. Diabetes Metab (2003) 0.87
Importance of human gastric lipase for intestinal lipolysis: an in vitro study. Biochim Biophys Acta (1986) 0.87
[Obstructive jaundice caused by granulomatous stenosis of the extrahepatic bile ducts in sarcoidosis]. Gastroenterol Clin Biol (1989) 0.87
Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2. Metformin inhibits the stimulating effect of insulin. J Clin Invest (1993) 0.86
Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study. Diabetes Metab (2012) 0.86
Altered erythrocyte n-3 fatty acids in Mediterranean patients with coronary artery disease. Int J Cardiol (2001) 0.86
Association of diabetic neuropathy with Na/K ATPase gene polymorphism. Diabetologia (1997) 0.86
Intestinal phospholipase, a novel enzyme. J Clin Invest (1982) 0.86
The increased frequency of the Lewis negative blood group in a diabetic population. Diabetologia (1978) 0.86
Charcot's foot: newest findings on its pathophysiology, diagnosis and treatment. Diabetes Metab (2010) 0.86
Modulation of mouse cerebral Na+,K(+)-ATPase activity by oxygen free radicals. Neuroreport (1995) 0.86
Randomized comparison of metabolic control achieved by intraperitoneal insulin infusion with implantable pumps versus intensive subcutaneous insulin therapy in type I diabetic patients. Diabetes Care (1992) 0.85
Passive transfer of lymphocytes from diabetic man to athymic mouse. Lancet (1979) 0.85
Treatment of diabetes mellitus using an external insulin pump: the state of the art. Diabetes Metab (2008) 0.85
Paradoxical lessening of autoimmune processes in non-obese diabetic mice after infection with the diabetogenic variant of encephalomyocarditis virus. Eur J Immunol (1990) 0.85
Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women. Int J Obes Relat Metab Disord (1998) 0.85
Obesity and diabetes. Acta Diabetol Lat (1981) 0.84
Determination of portal insulin absorption from peritoneum via novel nonisotopic method. Diabetes (1990) 0.84
[Neonatal hemoperitoneum: role of ultrasonography. Experience with 4 cases]. Radiol Med (1994) 0.84
[Eosinophilic cell pancreatitis in newborn infants of diabetic mothers]. Ann Anat Pathol (Paris) (1968) 0.84
Daytime fluctuations of plasminogen activator inhibitor 1 (PAI-1) in populations with high PAI-1 levels. Thromb Haemost (1992) 0.83
Hepatitis C virus genotypes implicated in mixed cryoglobulinemia. J Med Virol (1998) 0.83
Origins of neutral sterols in human feces studied by stable isotope labeling (D and 13C). Existence of an external secretion of cholesterol. Digestion (1981) 0.83
Human gastric lipase. The effect of amphiphiles. Eur J Biochem (1986) 0.83
Human gastric lipase: a sulfhydryl enzyme. J Biol Chem (1988) 0.83
Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies. Diabetes Metab (2008) 0.83
Reduced metabolic efficiency of skeletal muscle energetics in hyperthyroid patients evidenced quantitatively by in vivo phosphorus-31 magnetic resonance spectroscopy. Metabolism (1998) 0.83
Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin. Diabetes Obes Metab (2014) 0.83
Hypofibrinolysis and insulin-resistance. Diabete Metab (1991) 0.83
Treating type 2 diabetes: how safe are current therapeutic agents? Int J Clin Pract (2009) 0.83